Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 63-75

  Zollinger, Markus ^a   Lozac'h, Frédéric ^a   Hurh, Eunju ^b   Emotte, Corinne ^a   Bauly, Hounayda ^a   Swart, Piet ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Absorption; Distribution; Excretion; Hedgehog; Metabolism; Sonidegib (LDE225)

Indexed keywords

AMIDE; CARBON 14; MORPHOLINE; SONIDEGIB;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIET RESTRICTION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MYALGIA; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; BENZOATES; BIPHENYL COMPOUNDS; CARBON RADIOISOTOPES; FECES; GLUCURONIDES; HALF-LIFE; HUMANS; HYDROLYSIS; INTESTINAL ABSORPTION; MALE; METABOLIC DETOXICATION, DRUG; MOLECULAR STRUCTURE; MYALGIA; OXIDATION-REDUCTION; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84903816561     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2468-y     Document Type: Article

References (17)

1. Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805:181-208
2. Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903-911
3. McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1-114 (Pubitemid 137639458)
4. Scales SJ, de Sauvage FJ (2009) Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303-312
5. Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AMC, Dodd S, Tuntland T, Maniara W, Kelleher JF III, Yao Y-M, Warmuth M, Williams J, Dorsch M (2010) Discovery of NVPLDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 1:130-134
6. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, Garcia-Echeverria C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2:51ra70
7. Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16:2743-2748 (Pubitemid 35253140)
8. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingham D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20:1900-1909
9. International Commission on Radiological Protection (ICRP) (2007) The 2007 recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37(2-4):116-117
10. Zoppi U, Crye J, Song Q, Arjomand A (2007) Performance evaluation of the new AMS system at Accium Biosciences. Radiocarbon 49:171-180
11. Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development - a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205-213
12. 14C via accelerator mass spectrometry. Anal Chem 75:2192-2196
13. 14C content and total carbon mass in biological samples. Nucl Instrum Methods Phys Res Sect B 268:1307-1308
14. Faed EM (1984) Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213-1249
15. Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16 (Pubitemid 36139819)
16. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141-PL146
17. Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T (2002) Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 30:404-413 (Pubitemid 34263825)